Skip to content

Trial Summary

A Phase 2/3, Randomized, Open-label Study to Compare Bempegaldesleukin Combined with Pembrolizumab Versus Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head and Neck Squamous-Cell Carcinoma with PD-L1 Expressing Tumors (PROPEL-36)

Acronym:

PROPEL-36

ACTRN/NCT /ethics:

NCT04969861

Scientific title:

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

Sponsor / Cooperative group:

Nektar Therapeutics

Trial & Patient Characteristics

Cancer TypeHead and Neck
Trial TypeTreatment
PhasePhase II; Phase III
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2022-03-09
Anticipated End Date2026-05-01

Participating Hospitals

HospitalCancer Research SA
Clinical Trial CoordinatorKelly Mead
Emailadmin@cancerresearchsa.com.au
Phone08 8359 2565
Principal InvestigatorDr Sarwan Bishnoi
Recruitment StatusRecruiting